Breaking AI & Tech News Analyzed

The US seafood industry is tackling a significant challenge: Americans' low fish consumption. With an average annual intake of about 19lb per person, the US lags far behind the global average of 45lb. In contrast, Iceland leads the world with an impressive 200lb of seafood per person per year.To crack the US market, the seafood industry has devised a strategy to make fish more appealing by making it look like meat. This approach involves creating products such as tuna that resembles chicken nuggets and salmon sticks that look like beef jerky. This tactic is similar to hiding vegetables in recipes for picky toddlers, but with a twist: it's about presentation rather than altering the product's nature.This isn't a new concept, as plant-based meat gained popularity when placed in the meat department rather than the vegetarian aisle. Similarly, fish-as-meat marketing has been around with products like tuna steaks and salmon burgers. However, the trend seems to be gaining momentum, with recent reports from the Seafood Expo circuit indicating a surge in interest.While this strategy may be effective, its environmental implications are questionable. With 348 million people in the US potentially increasing their seafood consumption, concerns about overfishing and the collapse of marine life arise. Guardian columnist George Monbiot has argued that there are almost no fish or shellfish that can be safely eaten if the goal is to save the oceans, suggesting that stopping fish consumption is a more impactful action.The success of this strategy may also be influenced by economic factors, such as food inflation and tariffs. If supply chains collapse due to global conflicts, the demand for Fishy Meat may become irrelevant as Americans struggle to afford basic food items.

Time‑Sensitive OfferThe discount window closes on April 10 at 11:59 p.m. PT. Early registrants can save up to $482 per pass, and groups can claim an additional 30% off bundle passes. If the standard pass price is $1,200 (typical for prior years), the $482 reduction equates to roughly a 40% discount, a significant cost saving for startups and investors alike.Event OverviewDates: October 13–15, 2026 (core conference) with side events October 11–17.Location: Moscone West, San Francisco.Attendance: 10,000+ founders, tech leaders and VCs.2025 Highlights: 20,000+ curated meetings, 10,000+ Expo Hall attendees.Key OpportunitiesStartup Battlefield 200: 200 selected early‑stage startups compete for $100,000 equity‑free funding and direct access to tier‑one VCs.Sector Tracks: AI, scaling, fintech, climate and more, delivering 200+ on‑stage conversations.Exhibitor Showcase: Over 300 startup exhibitors in the Expo Hall, providing high‑traffic exposure.Networking Tech: New targeted matchmaking tools to improve connection efficiency.Financial Impact of Early RegistrationAssuming a baseline pass price of $1,200, the $482 early‑bird discount reduces the cost to $718, freeing capital that can be redirected to product development or runway extension. For a team of five, the collective saving reaches $2,410, enough to cover a modest marketing campaign or a short‑term hiring boost.Action StepsRegister before the deadline to lock in the lowest rate of the year.Consider bundle passes for teams to capture the additional 30% group discount.Apply for Startup Battlefield 200 or nominate a peer startup.

Researchers at Rothamsted Research in Harpenden, Hertfordshire, have made a groundbreaking discovery in the field of food safety. By utilizing Crispr genome editing, they have successfully developed wheat that can be used to make bread with reduced levels of acrylamide, a toxic compound classified as a probable carcinogen.The innovation lies in the reduction of free asparagine, an amino acid in wheat that converts into acrylamide when bread is toasted, fried, or baked. Field trials over two years demonstrated that gene-edited wheat can have significantly lower concentrations of free asparagine without impacting crop yields. This translates into lower acrylamide formation in food products, making toasted bread safer for consumption.In tests, bread and biscuits made from the edited wheat showed substantially reduced acrylamide levels, with some bread samples having concentrations below detectable limits even after toasting. The Crispr editing targeted the gene responsible for asparagine production, achieving a reduction of up to 93% in free asparagine in dual-edited lines.Compared to conventional methods that achieved a 50% reduction in free asparagine but resulted in a 25% yield penalty, the Crispr-edited wheat offers a more efficient and effective solution. Dr. Navneet Kaur, a lead researcher, highlighted the potential of Crispr technology to deliver precise, beneficial changes in crop genetics, emphasizing the importance of supportive regulatory frameworks to unlock benefits for agriculture and food systems.The UK has become a global hub for gene editing research since Brexit, with the Genetic Technology (Precision Breeding) Act of 2023 facilitating the development and marketing of genetically modified crops. However, the future of these advancements may be influenced by negotiations with the EU over sanitary and phytosanitary agreements.Prof. Nigel Halford, who led the study, noted that low-acrylamide wheat could help food businesses meet safety standards without compromising product quality or incurring major costs, ultimately reducing consumers' dietary exposure to acrylamide.

The B Corp certification, a coveted ethical status for companies, has undergone its biggest overhaul in 19 years. B Lab, the organisation behind the certification, has raised the standards required to qualify, putting dozens of companies at risk of losing their status. Previously, companies could make up for poor performance in one area by scoring highly in another. However, the new system requires companies to meet 'non-negotiable' standards in every one out of seven categories, with attainment verified by a third-party audit. The overhaul has been partly motivated by changes to EU law that require companies boasting of any ethical standard, including B Corp status, to be rubber-stamped by an external organisation. Sources familiar with the process said that some of the 10,000 companies that have the status will need to improve ethical standards to recertify, which they must do every three years. Analysis by the Guardian of the publicly available B Corp database suggests hundreds are already at, or close to, the 80-point threshold required, even under the old, less onerous system. Of more than 2,000 UK B Corps, more than 60 score exactly 80 points, including the Kent-based digital marketing agency Sleeping Giant Media and VoucherCodes, a website that provides details of discount offers from leading brands. Larger companies will face more extensive requirements under the new standard, including declaring their tax policies and setting science-based emissions targets across all areas of the business. One source said the changes could even affect companies that now score highly, such as the private bank Coutts, which has a score of 107.6 and does not have to recertify until 2028. B Lab UK said: 'Our goal is not for every business to become a B Corp, but for every business to behave like one.'

Peptides are short chains of amino acids that naturally occur in the body, acting as hormones such as insulin, oxytocin and vasopressin, or as fragments released during protein digestion.In recent years, a wave of interest has turned these molecules into purported therapeutic agents for everything from weight loss to anti‑ageing and tissue repair. Prescription drugs like semaglutide (Wegovy) and tirzepatide (Mounjaro) are synthetic peptides that have undergone rigorous clinical testing and are approved for specific medical uses.However, a large portion of the market consists of unregulated, experimental peptides sold for self‑administration. These products often bypass the strict approval processes required for medicines, raising serious safety concerns.Who is using these products? Initially confined to a niche of powerlifters and bodybuilders in the 2010s, the audience has expanded dramatically. Influential figures such as podcaster Joe Rogan have promoted combinations like the “Wolverine stack” (BPC‑157 and TB‑500) for injury recovery, while other compounds—CJC‑1295, MK‑677, ipamorelin, and GHK‑Cu—are marketed for muscle growth and anti‑ageing. Social media platforms are now flooded with instructions on purchasing and injecting these substances.Scientific backing is scant. Reviews of the literature reveal that most experimental peptides have only been tested in animal or cell models. For example, BPC‑157 shows promise for tendon and muscle repair in pre‑clinical studies, but no randomized human trials have validated these effects. Similarly, TB‑4 and its synthetic analogue TB‑500 have demonstrated limited blood‑vessel formation in laboratory settings, yet human data are absent and both are listed as prohibited substances by the World Anti‑Doping Agency.Researchers also highlight a critical knowledge gap: dosage, frequency and treatment duration remain undefined, making self‑administration a gamble.Legal landscape in the UK is clear that peptides not classified as medicines fall outside the Medicines and Healthcare products Regulatory Agency’s (MHRA) remit. If a seller makes medicinal claims, the product must hold a marketing authorisation under the Human Medicines Regulations 2012. The MHRA warns that labeling items as “research use only” does not shield vendors from enforcement when evidence shows the products are intended for human consumption.Health risks are multi‑fold. Experts caution that benefits observed in animal studies do not guarantee safety in humans. Contamination with harmful impurities or bacterial endotoxins can trigger severe reactions, including septic shock. Injecting excess natural peptides may disrupt the body’s tightly regulated hormonal balance, potentially affecting multiple physiological pathways.There is also theoretical concern that augmenting peptide levels could accelerate tumour growth, as some cancers over‑express certain peptide pathways. While no direct cases have been documented, the possibility underscores the need for caution.Additional dangers include improper injection techniques (e.g., air embolism), unknown interactions with existing medications, and the lack of systematic monitoring of long‑term effects. As one researcher put it, “If something goes wrong, users may never notice until irreversible damage has occurred.”

Les Kiss is set to take over the Wallabies in July, inheriting a side desperate to climb back to the top of world rugby. He faces a tight schedule – 14 months and 19 Tests – before the 2027 Rugby World Cup that Australia will host. Describing his mandate, Kiss stresses that he is not aiming for a radical overhaul. "It's not a revolution, it's evolution," he told the Guardian. "Core values like discipline, accountability and strategic planning stay firmly in place." What makes Kiss an outlier is his background: a former rugby league international who never played union at senior level. He says this forced him to "earn his stripes" in the union code, learning that culture and standards in the locker room drive performance on the field. His personal story is rooted in a family that escaped the Hungarian Revolution and settled in Bundaberg, and a playing career that saw him sprint down the wing before a knee injury sidelined him for four years. Those experiences, he believes, forged the resilience he now brings to coaching. After a stint in marketing and junior coaching, Kiss transitioned to union coaching, first as a defence coach for the Springboks (2001‑02), then as an assistant with Ireland (2009‑15), director of Ulster Rugby, and finally a three‑year spell with London Irish in the Premiership. Returning to Australia in 2024 to lead the Queensland Reds, he guided the franchise to its most prolific try‑scoring season in three decades, back‑to‑back quarter‑final appearances and record crowd numbers. The Reds sit 4‑2 in the 2026 Super Rugby Pacific season and are eyeing a top‑four finish. Kiss’s coaching philosophy centres on connection. "Coaching is about rapport and building something strong together," he says, adding that he is fully invested and treats every team like family. His transition to the Wallabies will be smoothed by a close partnership with current head coach Joe Schmidt. The two have shared roughly 40 Tests, developing a strong rapport that Kiss believes will help him "understand the breakdown" and set the right structures for success. The emerging "Kiss army" already includes former All Blacks staffer Scott McLeod as defence coach, analyst Eoin Toolan, set‑piece specialist Tom Donnelly, scrum guru Mike Cron, and consultant Laurie Fisher. Skills coach Mick Byrne and U20s boss Chris Whitaker also remain on board. While his new responsibilities grow, Kiss assures fans he remains 100% committed to the Reds, vowing not to let the franchise down despite his expanding duties. On the player front, Kiss highlights a blend of seasoned talent and fresh faces that could power Australia’s World Cup campaign. The likes of Mark Nawaqanitawase, Max Jorgensen, former winger Dylan Pietsch, and NRL convert Zac Lomax are poised to add dynamism, while 18‑year‑old prodigy Treyvan Pritachard offers a glimpse of the future. Ultimately, Kiss believes the Wallabies embody a uniquely Australian style – inventive, physical, and expressive – forged in backyard games and a culture of resilience. "The Australian way isn’t formulaic; it’s about solving problems on the field in our own special way," he concludes.

The UK television landscape has undergone a significant change this Easter, as new regulations banning junk food advertising before 9pm have taken effect. For the first time, viewers will not be subjected to a barrage of advertisements for chocolate eggs and hot cross buns during their Easter celebrations.The regulations, which came into force at the beginning of the year, aim to tackle rising childhood obesity by prohibiting products high in fat, sugar, and salt from appearing in TV ads before 9pm. This move has resulted in a sugar-free viewing experience for UK audiences during Easter.The impact on the advertising industry has been notable, with TV advertising spending by confectionery and snacks brands almost halving year-on-year between October and February. Overall TV ad spend is down at least 15% year-on-year.Industry bodies and broadcasters have argued that the ban is more political PR than an effective policy, with the chief executive of ITV, Carolyn McCall, and former Channel 4 boss, Alex Mahon, pointing out that the government’s own research showed that the number of calories saved would be 1.7 a day, about a third of a Smartie.Campaigners argue that big food companies are compensating for the ban by upping marketing budgets on other media, such as outdoor media and radio. A battle is already brewing over the likely introduction of further restrictions, with the government launching a consultation on adopting a newer nutrient profiling model that would deem a far wider range of products too high in fat, salt, and sugar.

The recent video of McDonald's CEO Chris Kempczinski sampling the chain's new 'Big Arch burger' sparked widespread ridicule. This incident highlights a growing trend: CEOs and corporate leaders increasingly seeking to center themselves in the spotlight. This phenomenon, which can be termed 'CEOism,' raises important questions about the motivations behind it and its impact on consumers.Examples of CEOism abound. During the Super Bowl, the founder of Ring featured in the company's ad, only to face backlash for the dystopian undertones of the doorbell technology being promoted. In the sporting world, Fifa president Gianni Infantino has taken to inserting himself into high-profile events, including interrupting the start of the World Cup to give a welcoming address and unveiling the official sticker album.The reasons behind CEOism are complex and multifaceted. On one hand, companies are seeking to be seen as more relatable and approachable, which may explain why CEOs want to center themselves in advertising. On the other hand, the current cultural and political climate appears to have emboldened corporate leaders, who now seem more willing to express their opinions and insert themselves into public discourse.The article's author, Larry Ryan, expresses skepticism about the trend, suggesting that CEOs are mistaking interest in their products with interest in the people themselves. He longs for a time when CEOs focused on financial performance rather than seeking to be in the spotlight.However, some argue that audiences want to hear from the people behind brands and that 'CEOism' can be an effective marketing strategy. The success of podcasts like 'The Diary of a CEO' and social media influencers suggests that people may indeed be interested in hearing from corporate leaders.

Italian regulators have launched an investigation into Sephora and Benefit Cosmetics, both owned by the French luxury group LVMH, over allegations of using 'covert marketing strategies' to sell beauty products to young girls. The probes aim to determine if these brands have been targeting minors with skincare products, such as face masks, serums, and anti-ageing creams, potentially fuelling an unhealthy obsession with skincare known as 'cosmeticorexia'.The Italian Competition Authority stated that the investigations were opened over concerns that important information – such as warnings and precautions for cosmetics not intended for, or tested on, minors – may have been omitted or presented in a misleading manner. The regulator expressed concerns that the frequent and combined use of a wide range of cosmetics by minors, without proper awareness, may be harmful to their health.The trend of young girls and teenagers being drawn to high-end beauty products has been driven by skincare content produced by beauty influencers, many of whom are tweens and teens themselves. This phenomenon, known as 'Sephora kids', has met a backlash from dermatologists who argue that children do not require beauty products and that this early focus on appearance can create anxiety over how their skin looks.Sephora has previously sought to distance itself from this trend, with its North America CEO, Artemis Patrick, stating in a 2024 interview that 'we do not market to this audience'. However, the regulator alleges that the company has adopted a 'particularly insidious marketing strategy' involving the use of 'very young micro-influencers who encourage the compulsive purchase of cosmetics among young people, a particularly vulnerable group'. LVMH said that it, Sephora, and Benefit would 'fully cooperate with the authorities' but declined to comment further, reaffirming their strict compliance with applicable Italian regulations.